PDS Biotechnology (FRA:EU6) Research & Development: €14.31 Mil (TTM As of Mar. 2026)


FRA:EU6 PDS Biotechnology Corp FRA:EU6
31 GF Score
Price €0.77
! 1 Warning Sign
View Full Analysis

What is PDS Biotechnology Research & Development?

PDS Biotechnology FRA:EU6 -3.50% 31 Research & Development is €14.31 Mil as of Mar. 2026. GuruFocus rates FRA:EU6 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. PDS Biotechnology's Research & Development for the three months ended in Mar. 2026 was €2.99 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €14.31 Mil.

PDS Biotechnology  (FRA:EU6) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

PDS Biotechnology Research & Development Related Terms

PDS Biotechnology Research & Development Historical Data

* Premium members only.

The historical data trend for PDS Biotechnology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PDS Biotechnology Research & Development Chart

PDS Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.96 27.78 25.46 21.55 16.25

PDS Biotechnology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.39 3.65 3.90 3.76 2.99
FRA:EU6
31GF Score
PDS Biotechnology Corp FRA:EU6
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PDS Biotechnology Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €14.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €14.31 Mil mean?
PDS Biotechnology (FRA:EU6) has a Research & Development of €14.31 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on PDS Biotechnology and its competitors.
Is PDS Biotechnology's Research & Development too high?
PDS Biotechnology's current Research & Development is €14.31 Mil. Overall, PDS Biotechnology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does PDS Biotechnology's Research & Development compare to INKT and PMVP?
PDS Biotechnology's Research & Development of €14.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on PDS Biotechnology and its competitors. PDS Biotechnology's current Research & Development is €14.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PDS Biotechnology stock overvalued right now?
PDS Biotechnology (FRA:EU6) has a current Research & Development of €14.31 Mil. The current Research & Development is €14.31 Mil. PDS Biotechnology's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For PDS Biotechnology (FRA:EU6), the current Research & Development is €14.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PDS Biotechnology Business Description

Other Exchanges PDSB:USA
Address 303A College Road, East Princeton, NJ, USA, 08540
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
31GF Score

Get the complete analysis for FRA:EU6

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.77
Price